vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Smurfit Westrock (SW). Click either name above to swap in a different company.

Bristol Myers Squibb is the larger business by last-quarter revenue ($11.5B vs $7.7B, roughly 1.5× Smurfit Westrock). Bristol Myers Squibb runs the higher net margin — 23.3% vs 0.8%, a 22.5% gap on every dollar of revenue. On growth, Bristol Myers Squibb posted the faster year-over-year revenue change (11.0% vs 0.7%). Over the past eight quarters, Smurfit Westrock's revenue compounded faster (61.2% CAGR vs -3.0%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

Smurfit Westrock plc is an Irish company based in Dublin, Ireland that manufactures corrugated and paper-based packaging. Its stock is listed on the New York Stock Exchange and the London Stock Exchange.

BMY vs SW — Head-to-Head

Bigger by revenue
BMY
BMY
1.5× larger
BMY
$11.5B
$7.7B
SW
Growing faster (revenue YoY)
BMY
BMY
+10.3% gap
BMY
11.0%
0.7%
SW
Higher net margin
BMY
BMY
22.5% more per $
BMY
23.3%
0.8%
SW
Faster 2-yr revenue CAGR
SW
SW
Annualised
SW
61.2%
-3.0%
BMY

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BMY
BMY
SW
SW
Revenue
$11.5B
$7.7B
Net Profit
$2.7B
$63.0M
Gross Margin
16.4%
Operating Margin
3.3%
Net Margin
23.3%
0.8%
Revenue YoY
11.0%
0.7%
Net Profit YoY
8.8%
0.0%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
SW
SW
Q1 26
$11.5B
$7.7B
Q4 25
$12.5B
$7.6B
Q3 25
$12.2B
$8.0B
Q2 25
$12.3B
$7.9B
Q1 25
$11.2B
$7.7B
Q4 24
$12.3B
$7.5B
Q3 24
$11.9B
$7.7B
Q2 24
$12.2B
$3.0B
Net Profit
BMY
BMY
SW
SW
Q1 26
$2.7B
$63.0M
Q4 25
$1.1B
$97.0M
Q3 25
$2.2B
$246.0M
Q2 25
$1.3B
$-28.0M
Q1 25
$2.5B
$384.0M
Q4 24
$72.0M
$146.0M
Q3 24
$1.2B
$-150.0M
Q2 24
$1.7B
$132.0M
Gross Margin
BMY
BMY
SW
SW
Q1 26
16.4%
Q4 25
67.2%
18.2%
Q3 25
71.9%
19.6%
Q2 25
72.5%
19.1%
Q1 25
72.9%
20.6%
Q4 24
61.0%
19.1%
Q3 24
75.1%
17.6%
Q2 24
73.2%
23.3%
Operating Margin
BMY
BMY
SW
SW
Q1 26
3.3%
Q4 25
11.8%
5.1%
Q3 25
25.5%
6.6%
Q2 25
14.5%
3.2%
Q1 25
26.5%
7.2%
Q4 24
1.4%
5.3%
Q3 24
14.1%
0.7%
Q2 24
10.5%
8.2%
Net Margin
BMY
BMY
SW
SW
Q1 26
23.3%
0.8%
Q4 25
8.7%
1.3%
Q3 25
18.0%
3.1%
Q2 25
10.7%
-0.4%
Q1 25
21.9%
5.0%
Q4 24
0.6%
1.9%
Q3 24
10.2%
-2.0%
Q2 24
13.8%
4.4%
EPS (diluted)
BMY
BMY
SW
SW
Q1 26
$0.12
Q4 25
$0.54
$0.18
Q3 25
$1.08
$0.47
Q2 25
$0.64
$-0.05
Q1 25
$1.20
$0.73
Q4 24
$0.05
$-0.12
Q3 24
$0.60
$-0.30
Q2 24
$0.83
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
SW
SW
Cash + ST InvestmentsLiquidity on hand
$9.6B
Total DebtLower is stronger
$-42.2B
$980.0M
Stockholders' EquityBook value
$18.1B
Total Assets
$45.2B
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
SW
SW
Q1 26
$9.6B
Q4 25
$10.2B
$892.0M
Q3 25
$15.7B
$851.0M
Q2 25
$12.6B
$778.0M
Q1 25
$10.9B
$797.0M
Q4 24
$10.3B
$855.0M
Q3 24
$7.9B
Q2 24
$6.3B
$26.8K
Total Debt
BMY
BMY
SW
SW
Q1 26
$-42.2B
$980.0M
Q4 25
$44.8B
$13.4B
Q3 25
$48.7B
$13.3B
Q2 25
$48.9B
$13.3B
Q1 25
$49.5B
$12.9B
Q4 24
$49.4B
$12.5B
Q3 24
$49.5B
$13.2B
Q2 24
$52.0B
Stockholders' Equity
BMY
BMY
SW
SW
Q1 26
$18.1B
Q4 25
$18.5B
$18.3B
Q3 25
$18.6B
$18.4B
Q2 25
$17.4B
$18.3B
Q1 25
$17.4B
$17.9B
Q4 24
$16.3B
$17.4B
Q3 24
$17.1B
$18.0B
Q2 24
$17.0B
$14.5K
Total Assets
BMY
BMY
SW
SW
Q1 26
$45.2B
Q4 25
$90.0B
$45.2B
Q3 25
$96.9B
$45.6B
Q2 25
$94.7B
$45.7B
Q1 25
$92.4B
$44.6B
Q4 24
$92.6B
$43.8B
Q3 24
$93.7B
$45.0B
Q2 24
$94.6B
$26.8K
Debt / Equity
BMY
BMY
SW
SW
Q1 26
0.05×
Q4 25
2.43×
0.73×
Q3 25
2.63×
0.72×
Q2 25
2.81×
0.73×
Q1 25
2.85×
0.72×
Q4 24
3.03×
0.72×
Q3 24
2.89×
0.73×
Q2 24
3.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
SW
SW
Operating Cash FlowLast quarter
$204.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.24×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
SW
SW
Q1 26
$204.0M
Q4 25
$2.0B
$1.2B
Q3 25
$6.3B
$1.1B
Q2 25
$3.9B
$829.0M
Q1 25
$2.0B
$235.0M
Q4 24
$4.4B
$781.0M
Q3 24
$5.6B
$320.0M
Q2 24
$2.3B
$340.0M
Free Cash Flow
BMY
BMY
SW
SW
Q1 26
Q4 25
$1.6B
$612.0M
Q3 25
$6.0B
$523.0M
Q2 25
$3.6B
$307.0M
Q1 25
$1.7B
$-242.0M
Q4 24
$4.1B
$212.0M
Q3 24
$5.3B
$-192.0M
Q2 24
$2.1B
$163.0M
FCF Margin
BMY
BMY
SW
SW
Q1 26
Q4 25
12.8%
8.1%
Q3 25
49.0%
6.5%
Q2 25
29.0%
3.9%
Q1 25
15.1%
-3.2%
Q4 24
32.9%
2.8%
Q3 24
44.3%
-2.5%
Q2 24
16.9%
5.5%
Capex Intensity
BMY
BMY
SW
SW
Q1 26
Q4 25
3.0%
7.7%
Q3 25
2.6%
7.6%
Q2 25
2.9%
6.6%
Q1 25
2.3%
6.2%
Q4 24
3.1%
7.5%
Q3 24
2.7%
6.7%
Q2 24
2.1%
6.0%
Cash Conversion
BMY
BMY
SW
SW
Q1 26
3.24×
Q4 25
1.82×
12.32×
Q3 25
2.87×
4.61×
Q2 25
2.99×
Q1 25
0.80×
0.61×
Q4 24
61.65×
5.35×
Q3 24
4.62×
Q2 24
1.38×
2.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons